J Clin Neurol.
2025 Jan;21(1):89-91. 10.3988/jcn.2024.0387.
Cogan Syndrome in a Patient With Melanoma Treated With Targeted Chemotherapy
- Affiliations
-
- 1Dizziness Center, Clinical Neuroscience Center, Department of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea
- 2Departments of Neurology, Seoul National University College of Medicine, Seoul, Korea
- 3Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea Received August 29, 2024 Revised September 30, 2024 Accepted October 1, 2024 Correspondence Jeong-Yoon Choi, MD, PhD Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea Tel +82-31-787-7562 Fax +82-31-787-4059 E-mail saideiju@gmail.com Dear Editor, A 48-year-old male presented with blurred vision and pain in both eyes that had developed 10 weeks previously. He had been diagnosed with malignant melanoma 11 years previously, and the BRAF and MEK inhibitors dabrafenib and trametinib were started 3 months previously. He had received vaccination against influenza types A and B 1 week before symptom onset. His visual acuity was 0.8 on the right and 0.7 on the left, and there were bilateral conjunctival injections (Fig. 1A). Anterior chamber cells and posterior synechiae were observed in both eyes (Fig. 1B). Anterior uveitis was diagnosed, and topical prednisolone eyedrops led to partial improvement. Four weeks later he experienced sudden hearing loss in both ears and holocranial headache. The ocular symptoms also worsened. After discontinuing dabrafenib and trametinib, he was treated with 48 mg of oral methylprednisolone daily for 3
- 4Departments of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
- KMID: 2563361
- DOI: http://doi.org/10.3988/jcn.2024.0387
